// App-Quantinova.ai

: Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Researchers

Presenter

  • Michael L. Wang

Principal Investigators

  • Wojciech Jurczak

  • Pier Luigi Zinzani

  • Toby A. Eyre

  • Chan Y. Cheah

  • Chaitra S. Ujjani

  • Youngil Koh

  • Koji Izutsu

  • James N. Gerson

  • Ian W. Flinn

  • Benoit Tessoulin

  • Alvaro J. Alencar

  • Shuo Ma

  • Ewa Lech-Maranda

  • Joanna M. Rhodes

  • Krish Patel

  • Jennifer A. Woyach

  • Nicole Lamanna

  • Yucai Wang

  • Constantine S. Tam

  • John F. Seymour

  • Talha Munir

  • Hirokazu Nagai

  • Francisco Hernandez-Ilizaliturri

  • Anita Kumar

  • Andrew D. Zelenetz

  • Preetesh Jain

  • Binoj Nair

  • Donald E. Tsai

  • Minna Balbas

  • Richard A. Walgren

  • Paolo B. Abada

  • Chunxiao Wang

  • Junjie Zhao

  • Anthony R. Mato

Medical Centers

  • Indianapolis, IN

  • National Cancer Center Hospital, Tokyo, Japan

  • Division of Hematology, Mayo Clinic, ROCHESTER, MN

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia

  • Medical College of Wisconsin, Brookfield, WI

  • Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

  • Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL

  • MD ANDERSON CANCER CENTER, HOUSTON, TX

  • Lymphoma Program, Abramson Cancer Center, Philadelphia, PA

  • Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Hematology Department, Nantes University Hospital, Nantes, France

  • New York-Presbyterian/ Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Northwell Health Cancer Institute, New Hyde Park, NY

  • Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

  • Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA

  • Fred Hutchinson Cancer Center, University of Washington, Seattle, WA

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Sarah Cannon Research Institute, Nashville, TN

  • Roswell Park Cancer Institute, Buffalo, NY

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Department of Haematology, St James's University Hospital, Leeds, United Kingdom

  • Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Locations

  • United States

  • United Kingdom

  • Japan

  • Australia

  • Italy

  • Poland

  • France

  • Republic of South Korea

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved